Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug
Provention’s Therapy Delays Onset By Three Years
Sanofi has exited Type 1 diabetes research, but retains a large commercial infrastructure in the US and worldwide. • Source: Shutterstock 
